Clinical and molecular prognostic factors in adrenocortical carcinoma

Minerva endocrinologica
Rossella Libé

Abstract

Adrenocortical carcinoma (ACC) is a rare cancer, with an incidence less than 0.7-1.5 per 1 million people per year, with a poor prognosis. The overall survival (OS) depends on the ENSAT stage: in particular in metastatic ACC the OS varies from 10 to 20 months, with a 5-year survival around 10%. ACC has a different behavior, probably due to a different biology. For this reason, a careful prognostic classification is mandatory, in order to stratify the patients and propose a specific management. Prognostic factors can be divides in three groups: clinical factors (tumor stage, age, hormone-related symptoms), pathological factors (Weiss Score, mitotic count, Ki-67, SF-1 and AVA2, P53, beta-catenin immunohistochemistry, resection status), molecular factors (chromosomal aberrations, methylation profile, altered gene expression and miRNA expression, gene mutations). The best way to stratify ACC patients and propose the best therapeutic option is to combine clinical, pathological and molecular factors. Individualizing patients' prognosis and tumor biology appears as a necessary step for personalized medicine. In addition to tumor stage and tumor grade, the genomic classification may precise the risk stratification and thus help definin...Continue Reading

References

Jul 1, 1992·World Journal of Surgery·J A SøreideS O Thoresen
Mar 1, 1989·The American Journal of Surgical Pathology·L M WeissA L Vickery
Mar 1, 1984·The American Journal of Surgical Pathology·L M Weiss
Jun 1, 1993·Journal of Pediatric Surgery·C C SabbagaD Blucher
Jun 5, 2002·World Journal of Surgery·Jean-François HenryEric Mirallie
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E MichalkiewiczR C Ribeiro
Sep 17, 2005·Proceedings of the National Academy of Sciences of the United States of America·Amelia CimminoCarlo M Croce
Sep 29, 2005·European Journal of Endocrinology·Rossella Libé, Jérôme Bertherat
May 9, 2006·World Journal of Surgery·Electron KebebewAlex McMillan
Oct 26, 2006·The Journal of Clinical Endocrinology and Metabolism·Guillaume AssiéEric Baudin
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rossella LibèJérôme Bertherat
Sep 1, 2007·Molecular Endocrinology·Mabrouka DoghmanEnzo Lalli
Feb 19, 2008·Molecular Cancer Therapeutics·Elizabeth A StephanMichael J Demeure
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aurélien de ReynièsJérôme Bertherat
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas J GiordanoGary Hammer
Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irina VeytsmanTito Fojo
Nov 27, 2009·Expert Opinion on Emerging Drugs·David E Schteingart
Dec 10, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patsy Siok Hwa SoonStan B Sidhu
Jan 2, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Giovanni LughezzaniPierre I Karakiewicz
Mar 5, 2010·Journal of Molecular Endocrinology·Enzo Lalli
Jul 28, 2010·The Journal of Clinical Endocrinology and Metabolism·Silviu SbieraMartin Fassnacht
Aug 10, 2010·Langenbeck's Archives of Surgery·Barbra S MillerGerard M Doherty
Nov 23, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sébastien GaujouxFrédérique Tissier
Dec 1, 2010·Nature Reviews. Genetics·Benjamin Czech, Gregory J Hannon
Dec 8, 2010·Surgery·Harma K TurbendianThomas J Fahey
Aug 24, 2011·Endocrine-related Cancer·Deniz M ÖzataWeng-Onn Lui
Dec 29, 2011·Langenbeck's Archives of Surgery·Jens WaldmannEmily P Slater
Feb 18, 2012·Nature·Amaia Lujambio, Scott W Lowe
May 4, 2012·The New England Journal of Medicine·Martin FassnachtUNKNOWN FIRM-ACT Study Group
Jul 18, 2012·The American Journal of Pathology·Joanne H HeatonGary D Hammer
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BerrutiUNKNOWN ESMO Guidelines Working Group
Oct 25, 2012·The Journal of Clinical Endocrinology and Metabolism·Olivia BarreauJérôme Bertherat

❮ Previous
Next ❯

Citations

Feb 27, 2020·Cancers·Sara BedroseMouhammed Amir Habra
Jan 31, 2021·International Journal of Molecular Sciences·Vania Balderrama BrondaniMaria Candida Barisson Villares Fragoso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.